



Paris, March 9, 2021

## PRESS RELEASE

### **The Biotech Digital Campus joins forces with biotechnology schools and training organizations to develop the talents of tomorrow**

An unprecedented alliance serving the French bioproduction sector



"Recipient of a  
Future Investment Program award"

**The Biotech Digital Campus is a recipient of the Engineering Action for innovative professional and support training, funded by the Future Investment Program (PIA). Steered by a leading industrial consortium (bioMérieux, Novasep, Sanofi, Servier), it now joins forces with a panel of key players in biotechnology training: EASE, ENSTBB-Bordeaux INP, ESTBB, IFIS, Groupe IMT, MabDesign, Sup'Biotech. These schools and training organizations will support the Campus in developing its educational curricula, including digital training modules, intended for employees in the sector or in retraining, as well as for students and job seekers.**

#### **A federated ecosystem to support the development of biotechnology skills**

The Biotech Digital Campus aims to federate skills and differentiated knowledge in biotechnology and digital, by increasing collaboration within the sector and by offering a wider ecosystem of outlets dedicated to designing innovative and open educational content around industrial needs. This one-of-a-kind alliance is the result of the various players' desire to come together with the aim of structuring and supporting the development of biotechnology skills.

*"This alliance is unique in the world, and it symbolizes the very essence of the Biotech Digital Campus: A symmetry of attention to support French and European ambitions in bioproduction, for the provision of innovative health solutions accessible to the greatest number of people. The Campus is particularly committed to supporting the nationwide mobilization for youth employment: One youth, one solution"* announced Karim Vissandjee, General Manager of the Biotech Digital Campus.

#### **A historic alliance to support France's ambition: Become a European leader in bioproduction**

This digitized Campus will offer training courses with innovative, immersive teaching methods designed to optimize knowledge acquisition and memory anchoring by learners. The schools and training organizations will support the Campus in the development of its curricula, and will thus meet the major challenge of transforming education and training and supporting them with a world of innovation.

*"Schools and training organizations are committed to the Digital Biotech Campus, a space for the creation of shared values bringing together players from industry and academia, for the promotion of bioproduction"* collectively declared the educational players.

To date, a set of 13 educational pathways covering the entire bioproduction chain have been identified. From the design of the product to its delivery to the patient, the Campus uses various digital tools to emulate the essential elements of production (digital twins, *serious games*, immersive reality, virtual reality, augmented reality), as well as cognitive approaches supported by artificial intelligence to promote the understanding of processes and the acquisition of professional practices.

*“The Biotech Digital Campus together with the training organizations and schools will help to prepare professionals and future pharma professionals for the challenges of their professions, and will give them a path to bioproduction.”*



The Campus is financed by an exceptional public/private partnership, including €11.75 million as part of the PIA's “Professional training engineering and innovative offers” system, operated by the Caisse des Dépôts on behalf of the State (France), to which can be added the support of the Interindustrial Skills Operator and that of the Île de France Region, as well as a strong mobilization of industrial players in the sector, trained in consortium, for an investment of over €30 million.



**Press contact:**

Sébastien Béraud – [sberaud@hopscotch.fr](mailto:sberaud@hopscotch.fr) – 01 41 34 23 67

**ABOUT bioMérieux**

*Pioneering diagnostics*

A global player in the field of *in vitro* diagnostics for over 55 years, bioMérieux is a French company operating in 44 countries and serving over 160 countries with a large network of distributors. In 2019, bioMérieux's sales amounted to €2.7 billion, over 90% of which was generated internationally.

bioMérieux offers diagnostic solutions (systems, reagents, software, and services) that serve to determine the origin of a disease or contamination in order to improve patient health and ensure consumer safety. Its products are used primarily for the diagnosis of infectious diseases. They are also used to detect microorganisms in food, pharmaceutical and cosmetic products.



bioMérieux is a company listed on Euronext Paris.  
Code: BIM – ISIN Code: FR0013280286  
Reuters: BIOX.PA / Bloomberg: BIM.FP

[www.biomerieux.com](http://www.biomerieux.com)

**About Novasep**

Novasep provides cost-effective solutions for the sustainable production of molecules for life sciences and fine chemicals. Novasep's global offer includes process development services, turnkey purification equipment and systems, contract manufacturing services, as well as active complex molecules aimed at the pharmaceutical, biopharmaceutical, and fine chemicals sectors, at the food and functional ingredient markets, and at the various industries treating raw materials from fermentation and chemical synthesis.

<https://www.novasep.com/>

**About Sanofi**

Sanofi's vocation is to support those facing health difficulties. As a global biopharmaceutical company specializing in human health, we prevent disease with our vaccines and offer innovative treatments. We support both those suffering from rare diseases and the millions of people suffering from chronic illness.

Sanofi and its more than 100,000 employees in 100 countries transform scientific innovation into healthcare solutions around the world.

Sanofi, empowering life.

**About Servier**

Servier is a global pharmaceutical group governed by a Foundation. Relying on a solid geographical presence and revenue of €4.7 billion in 2020, achieved in 150 countries, Servier employs 22,500 people worldwide. Servier is an independent group that invests over 20% of its brand-name revenue in Research and Development every year. To accelerate therapeutic innovation for the benefit of patients, the Group is committed to open and collaborative innovation with academic partners, pharmaceutical groups, and biotech companies. It also integrates the patient's voice at the heart of its activities, from research to support beyond medication.

A leader in cardiology, the ambition of the Servier Group is to become a recognized and innovative player in oncology. Its growth is based on a sustained commitment to cardiovascular and metabolic diseases, oncology and immuno-inflammatory diseases, and neurosciences. To promote access to healthcare for all, the Servier Group also offers a range of quality generic drugs covering most pathologies. More information on the website

[www.servier.com](http://www.servier.com)